Fingolimod cuts multiple sclerosis relapses in pediatric patients

September 13, 2018

(HealthDay)—Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the Sept. 13 issue of the New England Journal of Medicine.

Tanuja Chitnis, M.D., from Massachusetts General Hospital in Boston, and colleagues compared outcomes in patients aged 10 to 17 years with relapsing who were randomized to receive (107 participants) or interferon beta-1a (108 participants) for up to two years.

The researchers found that the adjusted annualized relapse rate was 0.12 with fingolimod and 0.67 with interferon beta-1a. The annualized rate of new or newly enlarged lesions on T2-weighted magnetic resonance imaging was 4.39 with fingolimod and 9.27 with interferon beta-1a. Adverse events occurred in 88.8 percent of patients receiving fingolimod and 95.3 percent receiving interferon beta-1a. Serious adverse events occurred in 18 patients (16.8 and 6.5 percent, respectively). These serious adverse events included seizures (four patients), infection (four patients), and leukopenia (two patients) in the fingolimod group and infection (two patients) and supraventricular tachycardia (one patient) in the beta-1a group.

"Longer studies are required to determine the durability and safety of fingolimod in pediatric multiple sclerosis," the authors write.

Several authors disclosed financial ties to Novartis, which manufactures fingolimod and funded the study.

Explore further: Study of daclizumab yields mixed results in multiple sclerosis

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Study of daclizumab yields mixed results in multiple sclerosis

October 8, 2015
(HealthDay)—Multiple sclerosis patients taking daclizumab high yield process (HYP), a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling, ...

Fingolimod in new therapeutic indication: Added benefit not proven

October 10, 2014
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) ...

Rituximab tops other disease-modifying tx options in MS

January 9, 2018
(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published ...

Fingolimod in RRMS: Indication of added benefit in certain patients

July 6, 2015
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment ...

Fingolimod in multiple sclerosis: No hint of added benefit in new therapeutic indication

March 8, 2016
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification ...

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models

June 16, 2016
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which ...

Recommended for you

Cell study reveals how head injuries lead to serious brain diseases

November 16, 2018
UCLA biologists have discovered how head injuries adversely affect individual cells and genes that can lead to serious brain disorders. The life scientists provide the first cell "atlas" of the hippocampus—the part of the ...

Newborn babies' brain responses to being touched on the face measured for the first time

November 16, 2018
A newborn baby's brain responds to being touched on the face, according to new research co-led by UCL.

Sucking your baby's pacifier may benefit their health

November 16, 2018
Many parents probably think nothing of sucking on their baby's pacifier to clean it after it falls to the ground. Turns out, doing so may benefit their child's health.

No link between 'hypoallergenic' dogs and lower risk of childhood asthma

November 15, 2018
Growing up with dogs is linked to a lower risk of asthma, especially if the dogs are female, a new study from Karolinska Institutet and Uppsala University in Sweden shows. However, the researchers found no relation between ...

Precision neuroengineering enables reproduction of complex brain-like functions in vitro

November 14, 2018
One of the most important and surprising traits of the brain is its ability to dynamically reconfigure the connections to process and respond properly to stimuli. Researchers from Tohoku University (Sendai, Japan) and the ...

New brain imaging research shows that when we expect something to hurt it does, even if the stimulus isn't so painful

November 14, 2018
Expect a shot to hurt and it probably will, even if the needle poke isn't really so painful. Brace for a second shot and you'll likely flinch again, even though—second time around—you should know better.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.